1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > United States Market for Psoriatic Arthritis Pharmacotherapy

United States Market for Psoriatic Arthritis Pharmacotherapy

  • June 2012
  • -
  • Frost & Sullivan
  • -
  • 92 pages

This research service covers the United States psoriatic arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed and used as well as the background standard of care. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics and novel oral disease-modifying antirheumatic drugs (DMARDs).

Executive Summary
•The market for psoriatic arthritis (PsA) pharmacotherapeutics is currently comprised of a single class: tumor necrosis factor (TNF) inhibitors. Availability of alternative therapies for anti-TNF refractory patients represents a significant unmet need.
•Revenue generated from sales of TNF inhibitors for PsA in the United States was approximately $xxx.x million in 2011 and dominated by Amgen. Revenue for the PsA therapeutic area is expected to increase to approximately $x,xxx.x million in 2017, aided by the addition of several new therapies to the market.
•Novel therapies aimed at alternative targets such as interleukin 12/23 (IL-12/23), interleukin-17 (IL-17), interleukin-6 (IL-6), phosphodiesterase type 4 (PDE4) and janus kinase (JAK) are in active development, with a PDE4 inhibitor and an anti-IL-12/23 closest to approval for PsA.
•Development of therapies for this complex disease and market penetration is hindered by several factors including a perception of PsA as a milder disease compared to rheumatoid arthritis (RA), and incompletely understood pathogenesis.
•Although some therapies such as TNF inhibitors that are effective for the treatment of RA are also effective for PsA, this is not always the case due to differences between the two diseases.
•Accumulating evidence supporting the importance of prompt initiation of effective disease modifying therapy for better long-term outcomes for patients with PsA is driving development of novel therapies aimed at improving symptoms and slowing disease progression.
•Estimates of the prevalence of PsA vary widely, but it is generally considered to occur in approximately xx to xx percent of psoriasis sufferers, or approximately xxx,xxx to x.x million men and women in the United States.
•Diagnostic difficulties are thought to result in unawareness of the condition by many patients and significant under-treatment.

Table Of Contents

United States Market for Psoriatic Arthritis Pharmacotherapy
TABLE OF CONTENTS

Executive Summary 4
Market Overview 10
Psoriatic Arthritis Pharmacotherapeutics Market -
External Challenges: Drivers and Restraints 20
Forecast and Trends 30
Demand Analysis 41
Market Share and Competitive Analysis 44
TNF Inhibitor Segment Breakdown 54
Non-TNF Biologics Segment Breakdown 65
Novel Oral DMARDs Segment Breakdown 73
The Last Word 81
Appendix 86

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Dyslipidaemia: KOL Insight

Dyslipidaemia: KOL Insight

  • $ 8 085
  • Industry report
  • March 2016
  • by Firstword Pharma

Effective but expensive: will PCSK9 inhibitors find widespread use in cardiology? PCSK9 inhibitors could be game changers for dyslipidaemia patients. But high cost and long-term safety questions have ...

COPD: KOL Insight

COPD: KOL Insight

  • $ 8 085
  • Industry report
  • April 2016
  • by Firstword Pharma

Is the COPD treatment market poised for a fundamental shift? After years of dominance by a handful of brands, change is in the air for COPD treatment. Will deep set preferences finally be overturned, ...

Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms

Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms

  • $ 6 995
  • Industry report
  • April 2016
  • by GBI Research

Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms Summary Schizophrenia ...


Download Unlimited Documents from Trusted Public Sources

Dysfunction Drug Market and Diabetes Statistics in the UK and the US - Forecast

  • June 2016
    6 pages
  • Dysfunction Dru...  

    Therapy  

    Hormone  

  • United Kingdom  

    United States  

View report >

Therapy Market in the US

  • June 2016
    39 pages
  • Therapy  

    Blood Disease  

  • United States  

View report >

Diabetes Statistics in the UK

  • June 2016
    4 pages
  • Diabetes  

View report >

Related Market Segments :

Therapy

ref:plp2012

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.